Breaking News

Averica Appoints VP of Ops

January 22, 2016

Berger to oversee growth as an analytical development

Cynthia Berger, Ph.D., has been appointed vice president of operations, Averica. In this newly created position, Dr. Berger will oversee Averica's growth and development and will report to chief executive officer Jeff Kiplinger, Ph.D.
Averica is an analytical development CRO with specialized expertise in small molecule analysis and purification.
Dr. Berger previously served as project manager at PCI Synthesis, a CMO, where she managed multi-million dollar projects manufacturing APIs. She was also vice president and a co-founder of Pion Inc., an instrumentation company and CRO, where she developed and grew markets for instrumentation, established a contract research lab, and led the sale of Pion to a private investment group.
“We are excited to welcome Cindy, who will provide significant insight and guidance to our growth as an analytical development company,” said Dr. Kiplinger. “Cindy will be exploring new ways to expand our capabilities and enhance the value we bring to clients. She will also oversee the standardization of many of our processes as we move toward ISO 17025 certification and add GMP analytical capabilities. Her significant experience and strong understanding of the analytical services market, coupled with her strong operations, financial, and business background, make her an essential asset to the future of Averica.”

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems